[DVAX] Dynavax Technologies Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 547.86 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.1 Change: 0.05 (1.23%)
Ext. hours: Change: 0 (0%)

chart DVAX

Refresh chart

Strongest Trends Summary For DVAX

DVAX is in the long-term down -74% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases, and cancer. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a investigational adult hepatitis B vaccine which is in Phase III clinical trials. The company also develops DV1179, a TLR inhibitor of TLR 7 and TLR9 for the treatment of autoimmune and inflammatory diseases that is in Phase I clinical trials; AZD1419, a candidate drug for the treatment of asthma, which is in Phase I clinical trials; SD-101, a second-generation TLR 9 agonist for immunotherapy of cancer that is in Phase I clinical trials; and DV230, an adjuvant platform that is in preclinical studies. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the d

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding38.5 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -79.43% Sales Growth - Q/Q-72.46% P/E
P/E To EPS Growth P/S67.13 P/BV7.3 Price/Cash Per Share5.61
Price/Free Cash Flow-7.27 ROA-91.91% ROE-137.33% ROI
Current Ratio4.97 Quick Ratio Long Term Debt/Equity Debt Ratio0.27
Gross Margin Operating Margin-1271.85% Net Profit Margin-1263.31% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities140 K Cash From Investing Activities-10.52 M Cash From Operating Activities-24.14 M Gross Profit
Net Profit-26.22 M Operating Profit-26.45 M Total Assets112.17 M Total Current Assets101.98 M
Total Current Liabilities20.5 M Total Debt9.51 M Total Liabilities37.1 M Total Revenue630 K
Technical Data
High 52 week13.28 Low 52 week2.69 Last close4.21 Last change2.93%
RSI49.49 Average true range0.27 Beta1.07 Volume1.13 M
Simple moving average 20 days5.58% Simple moving average 50 days3.35% Simple moving average 200 days-33.22%
Performance Data
Performance Week11.08% Performance Month-7.47% Performance Quart11.08% Performance Half-37.35%
Performance Year-62.71% Performance Year-to-date-53.99% Volatility daily4.19% Volatility weekly9.37%
Volatility monthly19.2% Volatility yearly66.5% Relative Volume185.36% Average Volume1.62 M
New High New Low

News

2020-06-04 18:37:50 | Edited Transcript of DVAX earnings conference call or presentation 7-May-20 8:30pm GMT

2020-06-01 16:00:00 | Why Dynavax Stock Crushed It Today

2020-05-30 17:12:24 | Notable Insider Buys: Avis, Dynavax And Formula One

2020-05-29 16:29:00 | Dynavax Stock Soars 26.4% Today on COVID-19 Vaccine Hopes

2020-05-29 08:53:12 | Implied Volatility Surging for Dynavax Technologies DVAX Stock Options

2020-05-28 16:05:10 | Dynavax to Present at the William Blair 40th Annual Growth Stock Conference

2020-05-27 16:05:10 | Dynavax Technologies Announces Closing of $80.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2020-05-22 10:19:52 | Price Over Earnings Overview: Dynavax Technologies

2020-05-21 21:00:10 | Dynavax Technologies Announces Pricing of $70.0 Million Public Offering of Common Stock

2020-05-21 16:01:10 | Dynavax Technologies Announces Proposed Public Offering of Common Stock

2020-05-20 13:18:05 | Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More

2020-05-19 16:08:30 | 7 Biotech Stocks Wall Street Says Will Double or More

2020-05-19 09:00:00 | Why Dynavax Technologies Is Jumping Today

2020-05-19 07:16:23 | Dynavax Explodes 40% In Pre-Market On Phase 1 Covid-19 Vaccine News

2020-05-14 09:24:01 | Why Dynavax Technologies DVAX Stock Might be a Great Pick

2020-05-09 14:31:01 | Dynavax Technologies Corp DVAX Q1 2020 Earnings Call Transcript

2020-05-07 16:10:10 | Dynavax Announces First Quarter 2020 Financial Results

2020-04-30 12:33:04 | Dynavax Technologies DVAX Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

2020-04-28 16:10:10 | Dynavax Reports Interim Analysis of Ongoing Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

2020-04-23 16:10:10 | Dynavax to Report First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020

2020-04-23 13:44:11 | Price Over Earnings Overview: Dynavax Technologies

2020-04-20 08:15:12 | Gilead Increases Enrollment Target, Pharma Rally Continues

2020-04-17 08:44:12 | Dynavax Technologies DVAX in Focus: Stock Moves 9.1% Higher

2020-04-17 07:15:11 | Gilead Brings Likely Coronavirus Cure, Pharma Rallies on R&D

2020-04-16 07:30:10 | Dynavax and Sinovac Announce Collaboration to Develop a Coronavirus COVID-19 Vaccine

2020-04-15 08:26:12 | Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up

2020-04-09 14:06:00 | These 21 companies are working on coronavirus treatments or vaccines — here’s where things stand

2020-04-08 08:00:10 | Dynavax Donates 10,000 Doses of HEPLISAV-B® Vaccine to Emergency Healthcare Providers and Hospital Staff to Protect Against Hepatitis B Infections Amidst COVID-19 Pandemic

2020-04-02 16:30:10 | Dynavax Provides Business Update on COVID-19 Pandemic Impact

2020-03-31 14:13:00 | These 19 companies are working on coronavirus treatments or vaccines — here’s where things stand

2020-03-26 11:56:00 | Dynavax's stock rises 10% on expanded CEPI partnership

2020-03-26 11:56:00 | Dynavax's stock rises 10% on expanded CEPI partnership

2020-03-26 10:09:15 | 3 Biotech Stocks to Watch as the Race for a Coronavirus Vaccine Continues

2020-03-26 07:30:10 | Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus COVID-19

2020-03-24 08:30:10 | Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus COVID-19 Vaccine Candidate with CpG 1018 Adjuvant

2020-03-13 07:38:47 | Earnings Update: Dynavax Technologies Corporation Just Reported And Analysts Are Trimming Their Forecasts

2020-03-12 03:01:12 | Edited Transcript of DVAX earnings conference call or presentation 11-Mar-20 8:30pm GMT

2020-03-11 18:05:10 | Dynavax Technologies DVAX Reports Q4 Loss, Misses Revenue Estimates

2020-03-11 16:47:01 | Dynavax Technologies: Q4 Earnings Insights

2020-03-11 16:10:10 | Dynavax Announces Fourth Quarter and Full Year 2019 Financial Results

2020-03-11 14:30:00 | Dynavax Technologies Corp. to Host Earnings Call

2020-03-04 12:30:05 | Dynavax Technologies DVAX May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2020-03-02 08:00:10 | Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Preparedness CEPI Focused on the Development of a Coronavirus COVID-19 Vaccine

2020-02-28 07:55:24 | Dynavax Technologies Corporation NASDAQ:DVAX Insiders Increased Their Holdings

2020-02-24 16:05:10 | Dynavax to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11

2020-02-18 16:05:10 | Dynavax to Present at the Cowen 40th Annual Health Care Conference

2020-02-05 14:45:27 | While Risks Remain, VBI Vaccines Stock Is a Buy at Today’s Prices

2019-12-17 07:56:25 | The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

2019-12-16 16:15:10 | Dynavax Appoints Ryan Spencer as Chief Executive Officer and to Board of Directors

2019-12-13 12:00:38 | These Hedge Funds Snapped Up Dynavax Technologies Corporation DVAX Before Q4 Surge